1432/1/12/22 Advanz Pharma Corp v Competition and Markets Authority
Registered
Status
The President made an order on 18 February 2022 granting an extension of time for Advanz to file a notice of appeal in respect of the CMA's decision of 3 February 2022 regarding the supply of Prochlorperazine tablets in the UK (Case 50511-2).
By an Order of the President dated 26 April 2022, the time for the CMA to file a single consolidated Defence is extended to 20 June 2022.
Summary of appeal published on 16 May 2022.
A case management conference has been listed on 9 September 2022 with a time estimate of one day.
